{
    "clinical_study": {
        "@rank": "141388", 
        "arm_group": {
            "arm_group_label": "Teprotumumab", 
            "arm_group_type": "Experimental", 
            "description": "Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions"
        }, 
        "brief_summary": {
            "textblock": "A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular\n      Edema."
        }, 
        "brief_title": "A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth\n      Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Center-Involved\n      Diabetic Macular Edema (DME)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of diabetes mellitus with Hemoglobin A1c <8%\n\n          -  IGF 1 in serum > 145ng/mL\n\n          -  Women of child-bearing potential must have negative pregnancy test and be willing and\n             able to use two different methods of contraception, one of which must be oral\n             contraceptive or depot formulation. Males must be surgically sterile or agree to use\n             barrier contraception\n\n          -  DME of less than 12 months with retinal thickening due to DME involving the center of\n             the macula\n\n          -  Non-proliferative diabetic retinopathy of moderate severity equivalent to Electronic\n             Early Treatment Diabetic Retinopathy Study (ETDRS) level 47 or below\n\n          -  Best corrected electronic ETDRS letter score < 78 and > 24\n\n          -  DME on Optical Coherence Tomography > 250 \u03bcm\n\n        Exclusion Criteria:\n\n          -  Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication\n             greater than 15% in the previous 60 days.\n\n          -  Significant renal disease, myocardial infarction, stroke, transient ischemic attack,\n             acute congestive heart failure\n\n          -  Blood pressure > 180/110\n\n          -  Systemic anti-vascular endothelial growth factor (VEGF) treatment within four months\n             prior to enrollment\n\n          -  History of pan retinal photocoagulation within four months prior to enrollment\n\n          -  History of ocular surgery within four months prior to enrollment\n\n          -  History of systemic treatment with corticosteroids within 3 months prior to\n             enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103283", 
            "org_study_id": "DME01RV"
        }, 
        "intervention": {
            "arm_group_label": "Teprotumumab", 
            "description": "Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions", 
            "intervention_name": "Teprotumumab", 
            "intervention_type": "Drug", 
            "other_name": "RV 001"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Diabetic Macular Edema", 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beverley Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90211"
                }, 
                "name": "David S Boyer"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Center-Involved Diabetic Macular Edema (DME)", 
        "overall_contact": {
            "email": "kcgabriel2@verizon.net", 
            "last_name": "Kathie Gabriel, BSN, MFT", 
            "phone": "610-937-1932"
        }, 
        "overall_official": [
            {
                "affiliation": "Professor of Ophthalmology Duke Eye Center Duke University Medical Center", 
                "last_name": "Scott W Cousins, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Retina Vitreous Associates Beverley Hills, California", 
                "last_name": "David S Boyer, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects with adverse events, serious adverse events and early discontinuations due to adverse events. Number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.", 
            "measure": "Safety of RV001in subjects with Diabetic Macular Edema", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline to Week 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103283"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacodynamic measure includes change in Optical Coherence Tomography, Fluorescein Angiography and Stereoscopic color funds photos findings.", 
            "measure": "Safety of RV001in subjects with Diabetic Macular Edema", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline to Week 9"
        }, 
        "source": "River Vision Development Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "River Vision Development Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}